Exchange: NASDAQ·Updated 07:30 PM EST
CALC logo

CALC CalciMedica Inc

$1.30
$0.09
(7.69%)
Today
Closed $1.26
$0.04
(3.17%)
After Hours
Mkt Cap$8.69M
Vol91,264.00

About CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company, which engages in developing therapies for life-threatening inflammatory diseases. The firm's product candidate, Auxora, helps in treating acute pancreatitis and asparaginase-associated pancreatitis. The company was founded by Kenneth A. Stauderman and Gonul Velicelebi in 2007 and is headquartered in La Jolla, CA.
34

Bearish Sentiment

How do you feel about CALC?

Lay1a
$CALC The beatings continue. In my opinion this one belongs at $5 as there really hasn't been any news for the drop from $5 to $1.25.
7
pablo4
$CALC is presently very active in overnight trading. Who knows what tomorrow brings....but, clearly, there are some eyes on it.
7
pablo4
$CALC don't you imagine that shorts have the very same question us longs recently had....except in inverse fashion? Us longs were a short while back like "who keeps selling this lower and lower?" Shorts are now like "who keeps buying this higher and higher?"
7
pablo4
$CALC I added so much in the 1s and a lot of shares (as I posted here) while it kept trying to push from 1.10 to 1. So, when it hits 2, it's blue skies for me....and I'm not thinking about selling any anywhere close to 2. It's hard to believe it got that low.....the RSI hit 16. It's got a lot of rebound in it, IMO, and, as others are implying...what a time for a good news drop!! JMO
7
PSM_EmpowerTrading
🌅 Watchlist part 2 ✅ $CALC 1.50 support, above 2, potential to 2.30/2.70 ✅ $SLGB .30 support, above .40, potential to .50/.60 🎯 Ideal stop loss below current support 🚨 Avoid chasing long positions into strength near resistance ⏳⏳ $PLUG $AISP still in swing accumulation phase 🎯🎯 Goal is GR🤑🤑N, not GR🥵🥵D
6
MUBSN
$CALC more vol ah than during the session. Should open at this level on monday, from my point of view, this closing was only a oneoff trade before the closin, only 10k shares were needed
6
keokeostwiz
$CALC This shadowy behind the curtain daily AH activity will be an interesting exposure and at the time of motive divulgence will blow the top off of this 1.80 cover…..one can sense a new inertia pattern of AH accumulation that will soon leak into the open sessions providing fuel for share price liftoff…JMO
6
Profitone
$CALC Three potential triggers Announcement of a pharmaceutical partnership This could lead to a significant revaluation if it includes a substantial upfront payment and development funding. Acquisition offer This would be the most powerful catalyst for a sudden surge, depending on the valuation offered. Aggressive buying in the absence of corporate news This could trigger a speculative rally due to limited liquidity, though it would also be more vulnerable to a correction. My verdict I would say there are two distinct narratives for CALC: The corporate story: an experimental drug with potential, a need for funding, and possible collaboration opportunities. The stock market story: low free float, volatility, short positions, and expectations of sharp price movements. These two narratives could converge to drive an extraordinary rally, but they could also evolve independently.
6
mrtmermer80
$CALC Little bit of continous buying brought this to this level. I suspect tax harvesting fund is done now. We have to have more buying and volume. We can fo back to $4 level easily.
6
66Caprice327
$CALC Quite an interesting handful of sessions, especially today and into after-hours. The breakout looks technically convincing, with improving volume and buyers continuing to absorb available shares, but I'm still scratching my head over what's driving it. No obvious news or fundamental catalyst that I could find. Could be seller exhaustion, a liquidity-driven move, or perhaps accumulation ahead of something we don't yet know. Encouraging price action, certainly, but I'm curious whether this is the beginning of a sustained reversal or simply a temporary imbalance in supply and demand. Time will tell. I’m here for it. GL✊🏻
6
keokeostwiz
$CALC There is a very active institutional buyer accumulating very cheap shares and believe this accumulation will continue in anticipation of positive news....the inclination supports a buying thesis to $1.00 pre split or $5.00 post split a reflective point at which buying was robust in the past and represents a future purchasing objective of other institutions where corporate govern provisions forbid buying shares under $5.00.....SHOULD management announce positive news regarding funding, partnership or prospective sale a catalyst appears supporting a price explosion with an O/S count of 6.83 and free float at 3.8 million.....one can fairly anticipate management incentives to secure the $4 and $5 dollar warrants into company coffers in the very near future as current momentum and sentiment builds to some kind of resolution......JMO
6
Super_Marioo
$CALC - well they have cash but we need pipeline news - however we could blast off before any news similar to how the share price went to the toilet last few months.
5
mrtmermer80
$CALC Now MM put some big sell orders at $2 and above. A.. holes MM, people wants to buy and pay more, why dont you chage your algorithm back!!!
5
MUBSN
$CALC Steps that could follow: 1. Auxora AP partnership: A pharma partner provides an upfront payment and funds clinical development. 2. Stock revaluation: The deal reduces clinical and financial uncertainty, potentially attracting new investors. 3. Warrant exercise: Above $4.0165 and $5, warrant holders could inject up to $33.7M in additional capital (financing for the rest of the trials) Financial independence: CALC can advance the rest of its pipeline without relying entirely on further equity raises. One strategic partnership could kill two birds with one stone: secure funding for Auxora AP while triggering the share-price appreciation needed to unlock up to $33.7M in warrant proceeds, funding the rest of the pipeline.
5
mrtmermer80
$CALC All I am telling you guys, we didn’t have anything yet. This is nit even a volume. There is not even real selling. MM used short shares to stop the momentum and when we have a real volume things will go wild. Very undervalued and underrated stock.
5
keokeostwiz
$CALC Management understands the critical need of securing those $4 and $5 warrants…..the time is set to seize the day….CALC faces a crossroads into a questionable future without stable funding,partnership acquisition or just outright sale……Expediant decisions require urgent attention……Carpe Diem
5
Profitone
$CALC $CALC - well they have cash but we need pipeline news - however we could blast off before any news similar to how the share price went to the toilet last few months.
4
Profitone
$CALC CALC – CalciMedica A lean, focused biotech company with the capital to execute. Having concluded its AKI (acute kidney injury) trial, CalciMedica has maintained a disciplined focus on its two highest-value programs: pulmonary arterial hypertension (PAH) and acute pancreatitis. In June, the company raised approximately $49 million, earmarked specifically for its PAH program. In July, it reached an agreement with the FDA regarding the design of a Phase 2b trial for Auxora in acute pancreatitis, featuring a primary endpoint with the potential to support regulatory approval. Key upcoming catalysts include Phase 1b data for Auxora in PAH, expected in mid-2027, alongside an IND (Investigational New Drug) filing for oral CM5480, also slated for mid-2027. The company’s cash runway has been strengthened, its current valuation is significantly depressed, and it is actively participating in high-profile industry conferences (including a presentation at a Guggenheim event this week).
4
MUBSN
$CALC if we are not trading above 1.81 today, it is like we are in red for the today session
4
Action80gr
$CALC The discussion is understandable, but speculation about price manipulation and accumulation won’t move CALC forward. What shareholders need now is transparency, concrete progress on AP Funding, and measurable commercial developments. A green trading day is encouraging, especially in a weak market, but sustained volume and real catalysts are what will determine whether this recovery has substance. It’s time for management to deliver results, not just expectations.
2

Advertisement|Remove ads.